The nation of Zimbabwe has declined a major US healthcare agreement valued at 367 million US dollars (£272m) spanning five years due to the United States' demand for sensitive biological samples.
This move came to light following a official document from December was leaked, revealing that President Emmerson Mnangagwa deemed the agreement was "lopsided".
A government spokesperson has since stated that the United States was demanding access to genetic material for scientific study and profit while was unwilling to guarantee the benefits from any future medical innovations.
"We must now begin the challenging and unfortunate task of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for continued talks to secure a agreement agreeable to both sides so the nation's critical HIV programme can be sustained.
Broader Background
This development comes after a similar case in Kenya, where a high court suspended a related health funding agreement after legal challenges were raised about the safety of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government agreements to enhance openness and accountability.
According to statements, Sixteen African countries have to date agreed to similar health pacts, constituting over $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy through US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to surrender its genetic material and health information for a long time, with no equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our country would supply the raw materials for medical research without any certainty that the final treatments would be available to our population if a new disease outbreak arise."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its pursuit of bilateral deals were upending systems already established through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This system is intended to ensure that when a nation provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how subsequent collaboration could be structured in a way that honours the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the official position, but suggested that negotiations must proceed considering much of the country's Aids initiatives were funded by external financing.
"Where technical issues arise, such as those involving data governance or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," the group said.
The situation highlights the ongoing debate between accepting vital foreign assistance and safeguarding a country's data in an ever more interconnected world.